Skip to main navigation
 
Stay Informed | Contact Us | Careers
Corium Inc.
  • About Us
    • Leadership
    • Board of Directors
  • Pipeline & Products
    • Alzheimer’s Disease
    • Osteoporosis
    • Contraception
  • Technology
    • R&D Capabilities
    • Corplex
    • MicroCor
  • Partnering
  • Manufacturing
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Financials & Filings
    • Corporate Governance
    • Investor FAQs
  • About Us
    • Leadership
    • Board of Directors
  • Pipeline & Products
    • Alzheimer’s Disease
    • Osteoporosis
    • Contraception
  • Technology
    • R&D Capabilities
    • Corplex
    • MicroCor
  • Partnering
  • Manufacturing
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
    • Financials & Filings
      • SEC Filings
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Investor FAQs

Investors

Investors

10:58 AM EDT on Apr 24, 2018

Copyright Nasdaq. Minimum 15 minutes delayed.

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. In addition to its proprietary Alzheimer's program, the company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners.

Press Releases

  • Summary ToggleCorium to Present at the 17th Annual Needham Healthcare Conference
    MENLO PARK, Calif. , March 19, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple , Corium’s President and...
  • Summary ToggleCorium Prices Offering of $100 Million of 5% Convertible Senior Notes
    MENLO PARK, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the pricing of its offering of $100,000,000...
View all press releases »

Events & Presentations

  • Mar 27, 2018
    3:30 PM EDT

    17th Annual Needham Healthcare Conference

  • Feb 14, 2018
    2:03 PM EST

    LEERINK Partners 7th Annual Global Healthcare Conference

View all events & presentations »

Investor Relations

  • Overview
  • Press Releases
  • Events & Presentations
    • Press & Publications
  • Stock Information
    • Historic Stock Lookup
    • Investment Calculator
  • Financials & Filings
    • SEC Filings
  • Corporate Governance
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Investor FAQs

SHAREHOLDER TOOLS

  • Email Alerts
  • Download Library
  • Share this
  • Home
  • About Us
  • Pipeline & Products
  • Technology
  • Partnering
  • Manufacturing
  • Investors
  • Contact Us








© 2017 Corium International Inc.

  • Facebook
  • Google
  • LinkedIn
  • Twitter
  • RSS